Sales of domestically produced PD-1 in the first half of the year: Cinda Biologics 1.39 billion yuan, BeiGene, 800 million yuan

On August 6, 2021, BeiGene released its second-quarter financial report.
The PD-1 antibody tislelizumab sold 800 million yuan in the first half of the year, and Zebutinib sold 420 million yuan in the first half of the year
.

BeiGene's research and development expenses in the first half of the year were RMB 4.
37 billion, an increase of 15% compared to the first half of last year.
The growth rate has slowed down, but it still far exceeds that of other pharmaceutical companies and biotechnology companies
.

Cinda Bio's PD-1 antibody sales were 1.
39 billion yuan in the first half of the year (Lilly's caliber), BeiGene's PD-1 antibody sales were 800 million yuan in the first half of the year, and the gap was significantly narrowed
.

Summarize

The domestic PD-1 antibody market growth rate has slowed down, and the international market competition in the second half is also particularly important
.